AstraZeneca Pharma India Limited has secured official regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan (Enhertu) for additional cancer indications. The clearance expands access to precision oncology therapies for Indian patients facing advanced, hard-to-treat HER2-expressing solid tumors.
BENGALURU, India — Biopharmaceutical major AstraZeneca Pharma India Limited has secured regulatory permission from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute its blockbuster oncology treatment, Trastuzumab Deruxtecan (marketed globally as Enhertu), for an additional indication in India. Granted under Form CT-20 by the Directorate General of Health Services, the approval enables the commercial availability of the 100 mg/5 mL lyophilized concentrate vial across Indian healthcare facilities. This decision represents a critical expansion of precision medicine access for patients battling advanced HER2-expressing malignancies who have exhausted standard therapeutic options.
Regulatory Approvals and Expanded Indications
Under the newly granted clearance, AstraZeneca Trastuzumab Deruxtecan is indicated for adult patients presenting with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic therapy and lack satisfactory alternative treatment regimens. The regulatory nod establishes the antibody-drug conjugate (ADC) as a vital option across diverse oncological settings where effective second- and third-line options remain limited.
Prior to this regulatory milestone, AstraZeneca Trastuzumab Deruxtecan had obtained CDSCO clearance for specific indications, including unresectable or metastatic HER2-positive breast cancer, HER2-low metastatic breast cancer, and HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. By broadening the label to encompass additional HER2-expressing solid tumors, the drug regulator provides Indian oncologists with a broader mandate to administer biomarker-driven targeted therapies.
Targeted Mechanism and Clinical Trial Evidence
Jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, AstraZeneca Trastuzumab Deruxtecan utilizes an engineered HER2-directed antibody-drug conjugate technology. The therapeutic agent links a humanized anti-HER2 monoclonal antibody to a topoisomerase I inhibitor payload via a cleavable tetrapeptide-based linker. Once bound to HER2 receptors expressed on cancer cells, the complex is internalized, releasing the cytotoxic payload to destroy tumor cells while minimizing damage to adjacent healthy tissues.
The expanded regulatory approval in India draws upon robust multi-center clinical trials, including the global DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies. Clinical trial results demonstrated meaningful objective response rates and durable disease control across various solid tumor types expressing the HER2 biomarker, including biliary tract, bladder, cervical, endometrial, and pancreatic malignancies. These findings confirm that targeting HER2 overexpression offers clinically significant therapeutic efficacy regardless of the primary anatomical site of the tumor.
Market Impact and Patient Accessibility in India
In India, cancer burden metrics underscore an urgent need for advanced therapeutic interventions. While HER2 overexpression was historically associated primarily with breast and gastric cancers, modern diagnostic profiling shows that HER2 expression occurs across a wide spectrum of solid tumors. Patients diagnosed with advanced stages of these cancers frequently face aggressive disease progression and limited survival outcomes following standard platinum-based chemotherapies.
For healthcare systems, medical practitioners, and patients across India, the availability of AstraZeneca Trastuzumab Deruxtecan provides a target-specific alternative when conventional lines of treatment fail. From a commercial perspective, AstraZeneca Pharma India's expansion of its specialty oncology division strengthens its product portfolio in South Asia, tapping into rising demand for advanced biological therapies and precision diagnostic testing across major tertiary cancer hospitals.
Official Sources Section
All regulatory metrics, product specifications, and corporate details in this report are based on official statutory disclosures and press releases issued by AstraZeneca Pharma India Limited and the Central Drugs Standard Control Organisation (CDSCO).
Regulatory filings were verified through the regulatory reporting portals of the National Stock Exchange of India, BSE India, the Central Drugs Standard Control Organisation, and the official AstraZeneca India Portal.
Quote Section
Commenting on the regulatory milestone and clinical rationale, corporate leadership highlighted the importance of advancing precision medicine in Indian oncology:
"According to officials and regulatory releases, the CDSCO approval of AstraZeneca Trastuzumab Deruxtecan for expanded indications marks a significant step forward in addressing unmet medical needs for patients with advanced HER2-expressing cancers who have exhausted standard therapeutic options," corporate disclosures stated.
Medical affairs leadership at AstraZeneca Pharma India emphasized that routine screening for HER2 expression across solid tumor specimens will be essential to identifying eligible patients and optimizing long-term therapeutic outcomes.
Why It Matters
The approval of AstraZeneca Trastuzumab Deruxtecan for an additional indication brings significant practical implications:
Expanded Treatment Access: Delivers a bio-targeted antibody-drug conjugate option for Indian patients with advanced solid tumors who have limited therapeutic choices.
Diagnostic Advancement: Encourages broader adoption of IHC and ISH biomarker testing across pathology labs in India to identify HER2-expressing tumors beyond breast cancer.
Oncology Portfolio Growth: Reinforces AstraZeneca's market position in South Asia's growing precision oncology market.
Key Facts at a Glance
Regulatory Authority: Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, India.
Product Form: Trastuzumab Deruxtecan (Enhertu) 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion.
Approval Type: Form CT-20 import, sale, and distribution permission.
Drug Class: HER2-directed Antibody-Drug Conjugate (ADC).
Key Trial Basis: DESTINY clinical trial program evaluating HER2-expressing solid tumors.
FAQ Section
Q1: What is Trastuzumab Deruxtecan and how does it work?
A1: Trastuzumab Deruxtecan (Enhertu) is an antibody-drug conjugate (ADC) combining a HER2-directed monoclonal antibody with a topoisomerase I inhibitor payload. It binds specifically to HER2 receptors on cancer cells to deliver chemotherapy directly into target tumor cells.
Q2: Which new indication did AstraZeneca Pharma India receive approval for?
A2: The CDSCO granted approval to import and sell Trastuzumab Deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic therapy and have no satisfactory alternative treatment options.
Q3: Which cancer types can express the HER2 protein?
A3: Beyond breast and gastric cancers, HER2 overexpression can occur in biliary tract, bladder, cervical, endometrial, non-small cell lung, and pancreatic malignancies.
Q4: How does this decision impact healthcare in India?
A4: It provides oncologists with a regulatory-approved precision therapy for advanced cancer cases, helping bridge critical treatment gaps for patients with hard-to-treat solid tumors.
Source: Central Drugs Standard Control Organisation, National Stock Exchange of India, BSE India, AstraZeneca India Portal
